Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

CMC Biologics Acquires XOMA’s Berkeley, CA Manufacturing Facility

By Pharmaceutical Processing | July 31, 2012

CMC Biologics, a contract manufacturing organization known for its in process development and cGMP manufacture capabilities, today announced the acquisition of XOMA Corporation’s, large-scale manufacturing operations and affiliated assets located in Berkeley, California. Financial terms of the transaction were not disclosed.

“We are very pleased to expand our clinical and commercial manufacturing operations to one of largest and most robust biotechnology clusters in the world,” said Claes Glassell, Chief Executive Officer of CMC Biologics. “Establishing a facility in the Bay Area complements our existing facilities located in Bothell, Washington and in Copenhagen Denmark, and supports our continued growth and addresses the growing demand of our customers for cGMP clinical and commercial production of biopharmaceuticals.” The fully functional 31,000 square foot facility is a completely equipped biological manufacturing operation, including three 2750L stainless steel bioreactors and two purification suites, as well as warehouse and office space. CMC Biologics expects to begin offering contract manufacturing services from this location immediately following the close of the transaction.

In June, CMC Biologics received Certificate of Good Manufacturing Practice (GMP) Compliance for commercial manufacturing issued by the Medicines and Healthcare products Regulatory Agency (MHRA).  CMC Biologics’ commitment to compliance and high quality systems resulted in the success of this important regulatory milestone and demonstrates excellence in the Company’s manufacturing, process, and quality systems.

 

 

Related Articles Read More >

Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE